Scienture Holdings, Inc. (SCNX) - Total Liabilities
Based on the latest financial reports, Scienture Holdings, Inc. (SCNX) has total liabilities worth $13.84 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Scienture Holdings, Inc. net asset momentum to track the company's year-over-year net asset growth rate.
Scienture Holdings, Inc. - Total Liabilities Trend (2006–2025)
This chart illustrates how Scienture Holdings, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Scienture Holdings, Inc. to measure how efficiently the company converts operating cash flow to free cash.
Scienture Holdings, Inc. Competitors by Total Liabilities
The table below lists competitors of Scienture Holdings, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Southern Hemisphere Mining Ltd
AU:SUH
|
Australia | AU$574.02K |
|
Leaders Cosmetics Co. Ltd
KQ:016100
|
Korea | ₩40.13 Billion |
|
Libet S.A.
WAR:LBT
|
Poland | zł22.31 Million |
|
Asuransi Jasa Tania Tbk
JK:ASJT
|
Indonesia | Rp255.97 Billion |
|
Biotechnology Assets S.A.
MC:BST
|
Spain | €7.01 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM71.48 Million |
|
Neungyule Education Inc
KQ:053290
|
Korea | ₩15.52 Billion |
|
DeepMarkit Corp
V:MKT
|
Canada | CA$653.62K |
Liability Composition Analysis (2006–2025)
This chart breaks down Scienture Holdings, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Scienture Holdings, Inc. market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scienture Holdings, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scienture Holdings, Inc. (2006–2025)
The table below shows the annual total liabilities of Scienture Holdings, Inc. from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $14.06 Million | -45.47% |
| 2024-12-31 | $25.78 Million | +115.02% |
| 2023-12-31 | $11.99 Million | +256.10% |
| 2022-12-31 | $3.37 Million | +68.70% |
| 2021-12-31 | $2.00 Million | +79.25% |
| 2020-12-31 | $1.11 Million | -22.20% |
| 2019-12-31 | $1.43 Million | +3.50% |
| 2018-12-31 | $1.38 Million | +48.80% |
| 2017-12-31 | $929.41K | -37.42% |
| 2016-12-31 | $1.49 Million | -15.65% |
| 2015-12-31 | $1.76 Million | +217.99% |
| 2014-12-31 | $553.68K | +102.81% |
| 2013-12-31 | $273.00K | -99.44% |
| 2008-12-31 | $48.70 Million | +239975.92% |
| 2007-12-31 | $20.28K | +479.54% |
| 2006-12-31 | $3.50K | -- |
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of… Read more